# Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer

> **NCT06202313** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Shengjing Hospital** · enrollment: 128 (estimated)

## Conditions studied

- Triple Negative Breast Cancer

## Interventions

- **BIOLOGICAL:** Cadonilimab
- **DRUG:** Eribulin

## Key facts

- **NCT ID:** NCT06202313
- **Lead sponsor:** Shengjing Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-02-10
- **Primary completion:** 2025-12-30
- **Final completion:** 2028-12-30
- **Target enrollment:** 128 (ESTIMATED)
- **Last updated:** 2024-01-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06202313

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06202313, "Study of Cadonilimab (AK104) Plus Eribulin vs. Eribulin Monotherapy for Recurrent or Metastatic Triple-negative Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06202313. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*